ArticleCancer immunology, immunotherapy : CII2020

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.

Alessio Cortellini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.